September 2016
Volume 57, Issue 12
Open Access
ARVO Annual Meeting Abstract  |   September 2016
Predictive Value of Peripapillary Retinal Nerve Fiber Layer Thickness in Patients with Retinal Vein Occlusion
Author Affiliations & Notes
  • Anton M Kolomeyer
    UPMC, Pittsburgh, Pennsylvania, United States
  • Yun Ling
    UPMC, Pittsburgh, Pennsylvania, United States
  • Eric Duerr
    UPMC, Pittsburgh, Pennsylvania, United States
  • Gadi Wollstein
    UPMC, Pittsburgh, Pennsylvania, United States
  • Joseph N Martel
    UPMC, Pittsburgh, Pennsylvania, United States
  • Footnotes
    Commercial Relationships   Anton Kolomeyer, None; Yun Ling, None; Eric Duerr, None; Gadi Wollstein, None; Joseph Martel, None
  • Footnotes
    Support  National Institute of Health R01-EY013178, P30-EY008098 (Bethesda, MD), Eye and Ear Foundation (Pittsburgh, PA), Research to Prevent Blindness (New York, NY).
Investigative Ophthalmology & Visual Science September 2016, Vol.57, 4167. doi:
  • Views
  • Share
  • Tools
    • Alerts
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Anton M Kolomeyer, Yun Ling, Eric Duerr, Gadi Wollstein, Joseph N Martel; Predictive Value of Peripapillary Retinal Nerve Fiber Layer Thickness in Patients with Retinal Vein Occlusion. Invest. Ophthalmol. Vis. Sci. 2016;57(12):4167.

      Download citation file:

      © ARVO (1962-2015); The Authors (2016-present)

  • Supplements

Purpose : To determine the predictive value of peripapillary retinal never fiber layer (pRNFL) thickness in patients with retinal vein occlusion (RVO).

Methods : Retrospective chart review of patients presenting within four weeks of developing a branch, hemiretinal, or central RVO (BRVO, HRVO, and CRVO, respectively). Main outcome measures included visual acuity (VA), intraocular pressure, pRNFL and central foveal thickness (CFT), intraocular injections, and complications.

Results : Thirty-three patients were included in the study (mean (SD) age, 69.8 (10.9) years; 61% female; mean (SD) follow-up, 27.2 (18.4) months; 58% HRVO/CRVO; 73% phakic). Presenting vs. final VA and IOP did not change significantly. Mean pRNFL thickness and CFT at final visit were significantly lower than on presentation (p<0.001 for both). Twenty-eight (85%) patients received a mean (SD) of 8.0 (7.9) anti-VEGF injections. Four (12%) patients developed complications related to neovascularization. Patients with HRVO/CRVO vs. BRVO had significantly worse VA (p=0.01) and higher pRNFL thickness (p=0.004) on presentation. Higher pRNFL thickness on presentation correlated with more anti-VEGF and total injections and shorter time to first anti-VEGF injection. Time to first anti-VEGF injection was shorter in patients with worse VA on presentation. Based on longitudinal analysis: 1) pRNFL thickness directly correlated with CFT and VA; 2) longer duration of follow-up and shorter time between visits directly correlated with higher number of anti-VEGF and total injections; and 3) longer duration of follow-up directly correlated with thinner pRNFL.

Conclusions : pRNFL thickness in patients with RVO may have predictive value in relation to associated visual sequelae requiring treatment and visual outcome.

This is an abstract that was submitted for the 2016 ARVO Annual Meeting, held in Seattle, Wash., May 1-5, 2016.


This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.